Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 4, 2012, Pages 286-292

  Winkler, Aaron R ^a   Nocka, Karl N ^a   Williams, Cara M M ^a  

^a PFIZER INC   (United States)

Author keywords

Cigarette smoke; COPD; Cytokines; Histone deacetylase; Macrophages

Indexed keywords

CIGARETTE SMOKE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYTOKINES; DOWN-REGULATION; ENZYME REPRESSION; HAZARDOUS SUBSTANCES; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LUNG; MACROPHAGES, ALVEOLAR; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TIME FACTORS; TOBACCO SMOKE POLLUTION;

EID: 84864041122     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.05.003     Document Type: Article

References (51)

1. Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004, 56(4):515-548.
2. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
3. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, 4:CD006829.
4. Tashkin D.P. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. Am J Med 2006, 119(10 Suppl. 1):63-72.
5. Wedzicha J.A., Calverley P.M., Seemungal T.A., Hagan G., Ansari Z., Stockley R.A., et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177(1):19-26.
6. Bel E.H. Smoking: a neglected cause of glucocorticoid resistance in asthma. Am J Respir Crit Care Med 2003, 168(11):1265-1266.
7. Chaudhuri R., Livingston E., McMahon A.D., Thomson L., Borland W., Thomson N.C., et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003, 168(11):1308-1311.
8. Lazarus S.C., Chinchilli V.M., Rollings N.J., Boushey H.A., Cherniack R., Craig T.J., et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007, 175(8):783-790.
9. Barnes P.J., Ito K., Adcock I.M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004, 363(9410):731-733.
10. Ito K., Ito M., Elliott W.M., Cosio B., Caramori G., Kon O.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352(19):1967-1976.
11. Ito K., Lim S., Caramori G., Chung K.F., Barnes P.J., Adcock IM I.M. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001, p. 00-0432fje.
12. Cosio B.G., Tsaprouni L., Ito K., Jazrawi E., Adcock IM I.M., Barnes P.J. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004, 200(5):689-695.
13. Ito K., Hanazawa T., Tomita K., Barnes P.l.J., Adcock I.M. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun 2004, 315(1):240-245.
14. Moodie F.M., Marwick J.A., Anderson C.S., Szulakowski P., Biswas S.K., Bauter M.R., et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. Faseb J 2004, 18(15):1897-1899.
15. Greene W.C., Chen L.F. Regulation of NF-kappaB action by reversible acetylation. Novartis Found Symp 2004, 259:208-217. discussion 218-25.
16. Barnes P.J. Alveolar macrophages as orchestrators of COPD. COPD: J Chronic Obstructive Pulm Dis 2004, 1(1):59-70.
17. Winkler A.R., Nocka K.H., Sulahian T.H., Kobzik L., Williams C.M. In vitro modeling of human alveolar macrophage smoke exposure: enhanced inflammation and impaired function. Exp Lung Res 2008, 34(9):599-629.
18. Chung K.F. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006, 7(6):675-681.
19. Churg A., Zhou S., Wang X., Wang R., Wright J.L. The role of interleukin-1{beta} in Murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol 2009, 40(4):482-490.
20. Ekberg-Jansson A., Andersson B., Bake B., Boijsen M., Enanden I., Rosengren A., et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. Respir Med 2001, 95(5):363-373.
21. Zeidel A., Beilin B., Yardeni I., Mayburd E., Smirnov G., Bessler H. Immune response in asymptomatic smokers. Acta Anaesthesiol Scand 2002, 46(8):959-964.
22. Borrill Z.L., Roy K., Vessey R.S., Woodcock A.A., Singh D. Non-invasive biomarkers and pulmonary function in smokers. Int J Chron Obstruct Pulmon Dis 2008, 3(1):171-183.
23. Roth M.D., Arora A., Barsky S.H., Kleerup E.C., Simmons M., Tashkin D.P. Airway inflammation in young marijuana and tobacco smokers. Am J Respir Crit Care Med 1998, 157(3 Pt 1):928-937.
24. Rovina N., Papapetropoulos A., Kollintza A., Michailidou M., Simoes D.C., Roussos C., et al. Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of chronic obstructive pulmonary disease?. Respir Res 2007, 8:53.
25. Willemse B.W., ten Hacken N.H., Rutgers B., Postma D.S., Timens W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res 2005, 6:38.
26. Kuschner W.G., D'Alessandro A., Wong H., Blanc P.D. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 1996, 9(10):1989-1994.
27. Culpitt S.V., Rogers D.F., Shah P., De Matos C., Russell R.E., Donnelly L.E., et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003, 58(11):942-946.
28. Culpitt S.V., Rogers D.F., Shah P., De Matos C., Russell R.E., Donnelly L.E., et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167(1):24-31.
29. Nagai S., Takeuchi M., Watanabe K., Aung H., Izumi T. Smoking and interleukin-1 activity released from human alveolar macrophages in healthy subjects. Chest 1988, 94(4):694-700.
30. Renoux M., Lemarie E., Renoux G. Interleukin-1 secretion by lipopolysaccharide-stimulated alveolar macrophages. Relationships to cell numbers-influence of smoking habits. Respiration 1989, 55(3):158-168.
31. Wesselius L.J., Nelson M.W., Bailey K., O'Brien-Ladner A.R. Rapid lung cytokine accumulation and neutrophil recruitment after lipopolysaccharide inhalation by cigarette smokers and nonsmokers. J Lab Clin Med 1997, 129(1):106-114.
32. Adcock I.M., Barnes P.J. Molecular mechanisms of corticosteroid resistance. Chest 2008, 134(2):394-401.
33. Barnes P.J. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004, 1(3):264-268.
34. Belvisi M.G. Regulation of inflammatory cell function by corticosteroids. Proc Am Thorac Soc 2004, 1(3):207-214.
35. Ito K., Getting S.J., Charron C.E. Mode of glucocorticoid actions in airway disease. Scientific World Journal 2006, 6:1750-1769.
36. Tuder R.M., Petrache I., Elias J.A., Voelkel N.F., Henson P.M. Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol 2003, 28(5):551-554.
37. Yang S.R., Chida A.S., Bauter M.R., Shafiq N., Seweryniak K., Maggirwar S.B., et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006, 291(1):L46-L57.
38. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269(1):7-17.
39. Epping M.T., Bernards R. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol 2009, 41(1):16-20.
40. Korner M., Tibes U. Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market. Prog Med Chem 2008, 46:205-280.
41. Lee M.J., Kim Y.S., Kummar S., Giaccone G., Trepel J.B. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 2008, 20(6):639-649.
42. Martínez-Iglesias O., Ruiz-Llorente L., Sánchez-Martínez R., García L., Zambrano A., Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008, 10(7):395-398.
43. Shankar S., Srivastava R.K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008, 615:261-298.
44. Akagawa K.S. Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Int J Hematol 2002, 76(1):27-34.
45. Di Stefano A., Caramori G., Oates T., Capelli A., Lusuardi M., Gnemmi I., et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002, 20(3):556-563.
46. Szulakowski P., Crowther A.J., Jiménez L.A., Donaldson K.M., Mayer R., Leonard T.B., et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174(1):41-50.
47. Leclerc O., Lagente V., Planquois J.M., Berthelier C., Artola M., Eichholtz T., et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 2006, 27(6):1102-1109.
48. van der Deen M., Timens W., Timmer-Bosscha H., van der Strate B.W., Scheper R.J., Postma D.S., et al. Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice. Respir Res 2007, 8:49.
49. Castro P., Legora-Machado A., Cardilo-Reis L., Valença S., Porto L.C., Walker C., et al. Inhibition of interleukin-1beta reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol 2004, 498(1-3):279-286.
50. Doz E., Noulin N., Boichot E., Guénon I., Fick L., Le Bert M., et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol 2008, 180(2):1169-1178.
51. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006, 203(1):7-13.